Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 31, 2018 - Sandoz announced the FDA approval of Hyrimoz (adalimumab-adaz), biosimilar to AbbVie’s Humira (adalimumab).
Download PDF
Return to publications
